Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.
Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...
The Python code (based on the Excel spreadsheet) was developed and is maintained by Bethany Atkinson at Dunad Therapeutics. Please send all queries regarding the Python code to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback